Have Insiders Sold DexCom Shares Recently?

Some DexCom, Inc. (NASDAQ:DXCM) shareholders may be a little concerned to see that the Executive Chairman, Kevin Sayer, recently sold a substantial US$2.9m worth of stock at a price of US$86.91 per share. That's a big disposal, and it decreased their holding size by 14%, which is notable but not too bad.

Check out our latest analysis for DexCom

DexCom Insider Transactions Over The Last Year

In fact, the recent sale by Executive Chairman Kevin Sayer was not their only sale of DexCom shares this year. They previously made an even bigger sale of -US$4.0m worth of shares at a price of US$134 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The good news is that this large sale was at well above current price of US$86.83. So it is hard to draw any strong conclusion from it.

Insiders in DexCom didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

I will like DexCom better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

Does DexCom Boast High Insider Ownership?

Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. It's great to see that DexCom insiders own 0.4% of the company, worth about US$121m. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

What Might The Insider Transactions At DexCom Tell Us?

Insiders haven't bought DexCom stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. But since DexCom is profitable and growing, we're not too worried by this. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn't make us feel confident about the company. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Every company has risks, and we've spotted 1 warning sign for DexCom you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.